B&K CORP-B

2396
3.4002.86% ( -0.100 )
Delay Closed: Nov 16, 16:08:11

Overview

B&K CORP-B (2396)

B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and ma...

Open
3.575
High
3.575
Low
3.215
Prev. Close
3.500
Volume
4.40K
Turnover
14.77K
Avg Price
3.356
Bid/Ask Ratio
-73.33%
Amplitude
10.29%
52wk High
37.200
Volume Ratio
0.36
Turnover Ratio
0.01%
52wk Low
3.005
HK Mkt Cap
282.28M
Market CapHKD
400.04M
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-2.39
EPSDynamic
-2.39
EPSStatic
--
BVPS
5.44
P/B
0.62
HK Shares
83.02M
Dividend YieldTTM
--
DividendTTM
--
Shares
117.66M
Min lot size
200
Currency
HKD

Daily Events

  1. Jul, 3

    B&K Corporation staged a sharp intraday reversal, opening lower but rallying in the afternoon session to close at HKD 4.300, up 5.65% from the previous close, with an intraday swing of 11.69% after hitting a 52-week low of HKD 3.850. The stock, which has plunged 88.44% from its 52-week high of HKD 37.2 and is down 73.16% YTD, remains below its 20-day (HKD 4.546) and 60-day (HKD 5.771) moving averages. The rebound was driven by news that the company enrolled its first patient in a Phase IIIa trial for a key burn treatment, alongside a 109.06% YoY revenue surge to approximately HKD 580,000 in Q4 2025, though its net loss widened to HKD 82.9 million. However, trading volume remained thin at 50,400 shares, with a turnover rate of just 0.06%.

  2. Jul, 2

    华芢生物-B 今日低开探底后小幅回升,收盘报 4.05 港元,跌 0.7%,主要因公司基本面持续承压且股价仍处弱势区间。盘中最低触及 3.62 港元,逼近 52 周低点 3.61 港元,距 52 周高点 37.20 港元跌幅达 89.1%;YTD 累计跌 74.7%,均线系统呈空头排列(MA20 4.60/MA60 5.83)。财报显示 Q4 2025 营收同比增 109% 至 58 万港元,但净亏损扩大 61.8% 至 8286 万港元,每股亏损 0.81 港元,盈利能力未见改善。消息面上,针对烧伤的 IIIa 期临床已启动首例入组,全年股东大会通过治理及资本授权决议。不过,全日成交仅 6000 股、换手率 0.01%,显示缺乏资金关注。

News